Loading
A phase 3 trial of DCVax-L in Glioma & glioblastoma and Brain and spinal cord tumours, run by Northwest Biotherapeutics, with a status the registry has not verified recently.
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer is a phase 3 interventional study registered as NCT00045968 by Northwest Biotherapeutics, with 348 participants planned, started 2006-12 and due to reach its primary completion in 2022-11. Interventions recorded: Dendritic cell immunotherapy. Conditions recorded: Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor.
Linked to the drug DCVax-L because the registry names it among its interventions and Glioma & glioblastoma and Brain and spinal cord tumours among its conditions. Registry record only: no result has been read by an editor.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.